Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioava…
Biotechnology
US, Redwood City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Biomea Fusion, Inc.'s gradings, price targets and earnings estimates. None
Reported
Past Estimate Consensus
Future Estimate Consensus
Biomea Fusion, Inc. can't present any analysts estimates at the moment detail analysis.